Stay updated on RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page revision updated from v3.4.1 to v3.4.2, indicating a minor front-end update. No substantive study data or content changes are evident.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check19 days agoChange DetectedRevision from v3.4.0 to v3.4.1; no changes to study content or site functionality were observed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no study details, contacts, locations, or outcomes were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a dedicated Locations section listing Beijing Municipality and Liaoning as study sites, replacing the previous location groupings.SummaryDifference0.2%

- Check85 days agoChange DetectedLast known status on the study record now shows 'Unknown status' with attribution to RemeGen Co., Ltd. and a verification timestamp (2023-11).SummaryDifference0.2%

- Check92 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2. There are no changes to study details, eligibility criteria, or trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RC48-ADC in HER2+ Metastatic Breast Cancer Clinical Trial page.